Table 1.
Baseline Characteristics by Sex and Weight Gain
| Characteristic | Total (n = 340) | Women and Men Who Gained Weight, 2.6–6.4 kg/m2 (n = 196) | Women and Men Who Maintained Weight, ± 0.5 kg/m2 (n = 144) | P Value, Weight Gain | Women (n = 166) | Men (n = 174) | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gained Weight (n = 96) | Maintained Weight (n = 70) | P Value, Weight Gain Within Women | Gained Weight (n = 100) | Maintained Weight (n = 74) | P Value, Weight Gain Within Men | |||||
| Clinical trial, n (%) | ||||||||||
| A5202 | 137 (40) | 82 (42) | 55 (38) | NAa | 42 (44) | 25 (36) | NAa | 40 (40) | 30 (41) | NAa |
| A5257 | 203 (60) | 114 (58) | 89 (62) | 54 (56) | 45 (64) | 60 (60) | 44 (59) | |||
| ART regimen, n (%) | ||||||||||
| ATV/r + NUCsb | 132 (39) | 74 (38) | 58 (40) | NAa | 34 (35) | 23 (33) | NAa | 40 (40) | 35 (47) | NAa |
| DRV/r + NUCsb | 66 (19) | 37 (19) | 29 (20) | 20 (21) | 17 (24) | 17 (17) | 12 (16) | |||
| EFV + NUCsb | 69 (21) | 43 (22) | 26 (18) | 26 (27) | 13 (19) | 17 (17) | 13 (18) | |||
| RAL + NUCsb | 73 (21) | 42 (21) | 31 (22) | 16 (17) | 17 (24) | 26 (26) | 14 (19) | |||
| Age, y, median (Q1, Q3) | 42 (33, 49) | 42 (34, 49) | 42 (33, 49) | NAa | 43 (35, 49) | 42 (34, 49) | NAa | 42 (33, 49) | 42 (31, 49) | NAa |
| Race/ethnicity, n (%) | ||||||||||
| White non-Hispanic | 111 (33) | 56 (29) | 55 (38) | .26 | 13 (14) | 16 (23) | .46 | 43 (43) | 39 (53) | .55 |
| Black non-Hispanic | 142 (42) | 89 (45) | 53 (37) | 56 (58) | 35 (50) | 33 (33) | 18 (24) | |||
| Hispanic | 81 (24) | 48 (24) | 33 (23) | 26 (27) | 18 (26) | 22 (22) | 15 (20) | |||
| Other | 6 (2) | 3 (2) | 3 (2) | 1 (1) | 1 (1) | 2 (2) | 2 (3) | |||
| Pre-ART BMI, kg/m2, median (Q1, Q3) | 25.6 (22.4, 29.0) | 25.4 (22.4, 29.5) | 25.9 (22.4, 29.0) | .70 | 27.1 (23.3, 32.8) | 27.7 (23.6, 32.3) | .69 | 24.1 (21.7, 27.6) | 24.2 (22.4, 27.1) | .74 |
| Pre-ART CD4, cells/mm3, median (Q1, Q3) | 273 (107, 394) | 195 (47, 337) | 344 (232, 460) | <.01 | 219 (56, 363) | 328 (231, 441) | <.01 | 174 (45, 299) | 361 (242, 465) | <.01 |
| Pre-ART HIV RNA, log10 copies/mL, median (Q1, Q3) | 4.70 (4.20, 5.09) | 4.84 (4.35, 5.35) | 4.47 (3.94, 4.80) | <.01 | 4.73 (4.00, 5.21) | 4..32 (3.72, 4.81) | <.01 | 4.95 (4.64, 5.43) | 4.54 (4.20, 4.80) | <.01 |
Abbreviations: 3TC, lamivudine; ABC, abacavir; ART, antiretroviral therapy; ATV/r, atazanavir/ritonavir; BMI, body mass index; DRV/r, darunavir/ritonavir; EFV, efavirenz; FTC, emtricitabine; HIV, human immunodeficiency virus; NA, not applicable; NUC, nucleos(t)ide analogue; RAL, raltegravir; TDF, tenofovir disoproxil fumarate.
aClinical trial, ART regimen, and age used in sampling design to enforce balance by these factors; therefore, no hypothesis testing performed.
bNUCS included TDF/FTC, or ABC/3TC (only with EFV or ATV/r).